Belvedere Trading
SMMT icon

Belvedere Trading’s Summit Therapeutics SMMT Stock Holding History

Belvedere Trading’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,400
Closed -$132K – 972
2024
Q4 		$132K Sell
7,400
-12,000
-62% -$233K ﹤0.01% 482
2024
Q3 		$425K Buy
19,400
+18,200
+1,517% +$255K ﹤0.01% 211
2024
Q2 		$9.36K Buy
+1,200
New +$6.48K ﹤0.01% 600
2024
Q1 		– Sell
-2,900
Closed -$7.57K – 940
2023
Q4 		$7.57K Sell
2,900
-1,400
-33% -$2.88K ﹤0.01% 710
2023
Q3 		$8.04K Buy
4,300
+100
+2% +$191 ﹤0.01% 549
2023
Q2 		$10.5K Buy
4,200
+1,500
+56% +$2.74K ﹤0.01% 715
2023
Q1 		$4.72K Buy
+2,700
New +$7.36K ﹤0.01% 792

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Belvedere Trading's SMMT Position: Q4 2024 in Review

Belvedere Trading sold out of Summit Therapeutics (SMMT) in Q4 2024, closing a stake of 1,548 shares — an estimated $30K sold.

Belvedere Trading first reported a position in SMMT in Q1 2023 and held it in 5 quarters. The position peaked at $33.9K in Q3 2024. 203 funds tracked by Wall St. Rank hold SMMT as of Q4 2024.

  • Belvedere Trading reported no remaining Summit Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Belvedere Trading sold 1,548 Summit Therapeutics shares in Q4 2024, an estimated $30K.
  • Belvedere Trading first reported a position in Summit Therapeutics in Q1 2023 and held it in 5 quarters.
  • Belvedere Trading's Summit Therapeutics position peaked at $33.9K in Q3 2024.
  • 203 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2024.

Based on Belvedere Trading's 13F filing for Q4 2024, filed 31 Jan 2025.